Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

NCT ID: NCT00708175

Last Updated: 2012-02-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 156 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-05-31
• Study Completion Date: 2011-02-28

Brief Summary

The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.

Detailed Description

The World Health Organization has estimated that 30% of all women aged over 50 years (postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any site being more than 2.5 standard deviations below the mean for young healthy adult women.

A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with correlations to duration of disease and poor glycemic control.

Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have not clearly identified a mechanism of bone loss. While there is evidence of increased bone fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism is not known. Initial studies with thiazolidinediones in humans have focused on short term exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute changes in circulating bone markers and bone density, but have been questioned because they may not represent bone metabolism in states of abnormal glucose metabolism. Impaired glucose tolerance has been identified not only as a risk factor for developing type 2 diabetes, but also at higher risk for known complications of diabetes. Examination of the effect of thiazolidinediones on bone metabolism in IGT patients will provide data in patients with abnormal glucose tolerance, but without the potential confounding effects of oral hypoglycemic medications to treat type 2 diabetes.

The primary objective of this study is to evaluate the effect of pioglitazone on bone mass and metabolism in postmenopausal women with impaired fasting glucose or impaired glucose tolerance. Total participation time in this study is approximately 1 year and six months.

Conditions

Bone Metabolism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Pioglitazone

Group Type: EXPERIMENTAL

Pioglitazone

Intervention Type: DRUG

Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.

Interventions

Pioglitazone

Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.

Intervention Type: DRUG

Placebo

Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.

Intervention Type: DRUG

Other Intervention Names

ACTOS®; ACTOS®

Eligibility Criteria

Inclusion Criteria

• Is female and has not experienced menses for at least 5 years.
• Has a Fasting Plasma Glucose level greater than or equal to 100 and less than 126 mg/dL or a 2-hour post-oral glucose tolerance test greater than or equal to 140 and less than or equal to 199 mg/dL at Screening.
• Has a body mass index greater than or equal to 16 and less than or equal to 40 kg/m2 and weighs less than 300 pounds (approximately 136 kilograms).
• Agrees to take daily supplements of Vitamin D (a minimum of 800 IU daily) and calcium (a minimum of 1000 mg daily) during the treatment and wash-out periods.
• Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis [fasted for at least 8 hours]) within the reference range for the testing laboratory unless the results are deemed not clinically significant by the investigator or sponsor.
• Is in good health as determined by the physician (ie, via medical history and physical examination) at Screening.

Exclusion Criteria

• Has a fasting triglyceride level greater than 500 mg/dL.
• Has a hemoglobinopathy causing anemia or interfering with glycosylated hemoglobin assays.
• Has an alanine transaminase level greater than or equal to 2.5 times the upper limit of normal, active liver disease or jaundice.
• Has Vitamin D (25-OH-D) less than 20 ng/mL.
• Has Baseline Bone Mineral Density defined as a T-score less than -2.0 at the total hip, spine, or femoral neck based on Caucasian reference values.
• Has unexplained microscopic or macroscopic hematuria confirmed by repeat testing.
• Has any of the following disorders:

• Rheumatoid Arthritis
• Thyroid (uncontrolled on thyroid replacement therapy), parathyroid, pituitary, nutritional, inflammatory, gastrointestinal, autoimmune, or renal or other disease known to affect bone metabolism.
• A personal history of kidney stones.
• Has a clinical history after age 45 of wrist, hip, or leg fractures.
• Has a history of more than 1 asymptomatic vertebral deformity or any vertebral deformity attributed to osteoporosis.
• Has a known history of drug abuse (defined as illicit drug use) or a known history of alcohol abuse within 2 years of Screening.
• Has signs and/or symptoms of heart failure.
• Is currently participating in another investigational study or has participated in an investigational study within the past 30 days or 5 half lives of the investigational product, whichever is longer.
• Has any other serious disease or condition at screening or at randomization that might make it difficult to successfully manage and follow up with the subject according to the protocol.
• Has a history of cancer, other than basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.
• Has a history of breast cancer.
• Is taking or has ever taken pioglitazone or other Thiazolidinediones.
• Has received or donated blood or blood products within 30 days preceding the Screening visit or plans to donate blood during the study.

• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

VP Clinical Science Strategy

Role: STUDY_DIRECTOR

Takeda

Locations

Greenbrae, California, United States

Los Banos, California, United States

San Diego, California, United States

Walnut Creek, California, United States

West Hills, California, United States

Lakewood, Colorado, United States

Longmont, Colorado, United States

Boynton Beach, Florida, United States

Hialeah, Florida, United States

Jupiter, Florida, United States

Dunwoody, Georgia, United States

Gainesville, Georgia, United States

Honolulu, Hawaii, United States

Idaho Falls, Idaho, United States

Chicago, Illinois, United States

Des Moines, Iowa, United States

Iowa City, Iowa, United States

Louisville, Kentucky, United States

Metarie, Louisiana, United States

Scarborough, Maine, United States

Bethesda, Maryland, United States

Detroit, Michigan, United States

Omaha, Nebraska, United States

Albuquerque, New Mexico, United States

Mineola, New York, United States

West Haverstraw, New York, United States

Pinehurst, North Carolina, United States

Cincinnati, Ohio, United States

Portland, Oregon, United States

Aiken, South Carolina, United States

Greenville, South Carolina, United States

Brentwood, Tennessee, United States

Denton, Texas, United States

Houston, Texas, United States

Countries

United States

References

Ipsen EO, Madsen KS, Chi Y, Pedersen-Bjergaard U, Richter B, Metzendorf MI, Hemmingsen B. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD013516. doi: 10.1002/14651858.CD013516.pub2.

Reference Type: DERIVED

PMID: 33210751 (View on PubMed)

Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013 Dec;98(12):4691-701. doi: 10.1210/jc.2012-4096. Epub 2013 Sep 20.

Reference Type: DERIVED

PMID: 24057294 (View on PubMed)

Related Links

http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&fileTypeCode=ACTOSPI

ACTOS® Package Insert

Other Identifiers

U1111-1115-0660

Identifier Type: REGISTRY

Identifier Source: secondary_id

AD-4833_402

Identifier Type: -

Identifier Source: org_study_id